Literature DB >> 2033259

Antithrombin III regulates complement activity in vitro.

J M Weiler1, R J Linhardt.   

Abstract

Heparin, a polyion, exerts its main activity to inhibit coagulation through a serine protease inhibitor, antithrombin III. Previous studies have clearly shown that heparin in the absence of antithrombin III also has the capacity to regulate C activity. The present studies examined the ability of purified human antithrombin III to regulate classical and alternative pathways of C, alone and in the presence of heparin. Antithrombin III alone inhibited generation of both pathways in a dose-related manner; antithrombin III at 8 micrograms/10(7) cellular intermediates inhibited generation of the classical and alternative pathway convertases by 60 and 42%, respectively. Antithrombin III and heparin augmented each other's capacity to inhibit generation of both convertases in a dose-related manner. Antithrombin III did not appear to inhibit on the basis of charge because it is only slightly anionic (isoelectric pH value, 5.0); instead, antithrombin III may have acted as a serine protease inhibitor of the proteolytic enzymes of the C cascades. Antithrombin III acted only to inhibit formation of the alternative pathway convertase but had no activity on terminal lysis by this pathway; similarly, antithrombin III inhibited preformed EAC1,4b,2a,3b but had no activity on classical pathway cellular intermediates containing additional components. Finally, antithrombin III inhibited consumption of factor B hemolytic activity in a reaction mixture that also contained factor D and C3b, suggesting that factor D activity was also inhibited. These studies demonstrate the capacity of antithrombin III to regulate C and suggest that, in concert with heparin, antithrombin III may play an important role in the regulation of C in vivo.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033259

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

Review 1.  Interaction between the coagulation and complement system.

Authors:  Umme Amara; Daniel Rittirsch; Michael Flierl; Uwe Bruckner; Andreas Klos; Florian Gebhard; John D Lambris; Markus Huber-Lang
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 2.  Interactions between coagulation and complement--their role in inflammation.

Authors:  Katerina Oikonomopoulou; Daniel Ricklin; Peter A Ward; John D Lambris
Journal:  Semin Immunopathol       Date:  2011-08-03       Impact factor: 9.623

3.  Human mannose-binding lectin inhibitor prevents myocardial injury and arterial thrombogenesis in a novel animal model.

Authors:  Vasile I Pavlov; Ying S Tan; Erin E McClure; Laura R La Bonte; Chenhui Zou; William B Gorsuch; Gregory L Stahl
Journal:  Am J Pathol       Date:  2014-12-04       Impact factor: 4.307

4.  Eosinophil granule cationic proteins regulate the classical pathway of complement.

Authors:  J M Weiler; R E Edens; C S Bell; G J Gleich
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

5.  Blood interactions with plasticised poly (vinyl chloride): influence of surface modification.

Authors:  Xiaobin Zhao; James M Courtney; Hua Q Yin; Robin H West; G D O Lowe
Journal:  J Mater Sci Mater Med       Date:  2007-07-10       Impact factor: 3.896

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.